Cellular Immunotherapy Market to Grow with a CAGR of 9.31% through 2028
Rising prevalence of cancer are expected to drive
the Global Cellular Immunotherapy Market growth in the forecast period,
2024-2028.
According to
TechSci Research report, “Cellular Immunotherapy Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Cellular Immunotherapy Market stood at USD 6.43 Billion in 2022 and
is anticipated to grow with a CAGR of 9.31% through 2028. The rising prevalence
of cancer is another impact rendering factor for the growth. According to
Globocan estimates, in 2020, an estimated 19.2 million new cancer cases were
reported worldwide and this number is projected to reach 24.5 million by 2030.
In 2020, cancer accounted for an estimated 10 million deaths. According to
Cancer Research U.K., more than 375,000 new cancer cases are reported each year
in the U.K. Also, based on WHO estimates, two-thirds of the population aging 60
years & above live in developing countries. Aging is the most common factor
that increases the risk of cancer. Therefore, the rising geriatric population
is expected to increase the prevalence during the forecast period, which will
drive the demand for cellular immunotherapies. However, the high cost of
cellular immunotherapy product manufacturing is expected to restrain the
growth. Cellular immunotherapy involves modified immune cells that make them
more sensitive to differentiate between healthy and cancer tissues. The
manufacturing process is complicated and expensive. The need for high capital
investment, a highly aseptic environment, and the presence of significant
operational difficulties are some of the factors that raise the cost of
cellular immunotherapy manufacturing, thereby increasing the overall cost of
the therapy.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Cellular Immunotherapy Market”
The Global Cellular
Immunotherapy Market is segmented into Therapy Type, Indication,
Indication, and company.
Based on the
Indication, the B-cell Malignancies segment is anticipated to witness
substantial market growth throughout the forecast period. The growth of the
Global Cellular Immunotherapy Market is anticipated to be significantly
propelled by the treatment of B-cell malignancies. Cellular immunotherapy,
particularly Chimeric Antigen Receptor T-cell (CAR-T) therapies, has
demonstrated remarkable efficacy in addressing B-cell malignancies such as
certain types of leukemia and lymphomas. These therapies involve the genetic
modification of a patient's T cells to express chimeric receptors, enabling
them to recognize and eliminate B-cell cancers with precision. The specificity
of cellular immunotherapy for B-cell malignancies addresses a critical unmet
medical need, especially in cases resistant to conventional treatments. The
success of CAR-T therapies in achieving deep and durable responses in patients
with relapsed or refractory B-cell malignancies has positioned these
interventions as groundbreaking treatments.
Based on the
End-Use segment, the Hospital Pharmacies segment has been the dominant force in
the market. Cancer institutes are poised to play a pivotal role in propelling
the growth of the Global Cellular Immunotherapy Market. These specialized
institutions, dedicated to advancing cancer research and treatment, serve as
epicenters for innovation, collaboration, and clinical trials focused on
cellular immunotherapies. Their expertise in understanding the intricacies of
cancer biology and their access to diverse patient populations position cancer
institutes as critical players in driving advancements in cellular
immunotherapy. Collaborative efforts between cancer institutes and
biopharmaceutical companies foster the development of novel cellular
immunotherapies. The infrastructure and resources within these institutes
accelerate the translation of groundbreaking research into clinical
applications, expediting the pathway to regulatory approvals and
commercialization. Moreover, cancer institutes often serve as hubs for training
healthcare professionals in the administration and management of cellular
immunotherapies, ensuring widespread adoption and dissemination of best
practices. Their influence extends beyond research and development, as they
contribute to shaping treatment guidelines and protocols, influencing
regulatory decisions, and raising awareness about the transformative potential
of cellular immunotherapy.
Major companies
operating in Global Cellular Immunotherapy Market are:
- Bristol-Myers Squibb
Company.
- Novartis AG.
- Gilead Sciences Inc.
(Kite Pharma)
- F. Hoffmann-La Roche
Ltd.
- Merck KGaA.
- GlaxoSmithKline plc.
- AstraZeneca Plc.
- Pfizer Inc.
- Johnson & Johnson.
- Celyad.
Download Free Sample Report
Customers can
also request 10% free customization on this report
“Some of the
major factors propelling the market growth are the development of advanced
cell-based therapies, the rising prevalence of cancer, and increasing R&D
investment by key companies. Moreover, the increasing number of product
approvals and growing adoption of these therapies for the treatment of cancer
is boosting the market growth. Aging is the
most common factor that increases the risk of cancer. Therefore, the rising
geriatric population is expected to increase the prevalence during the forecast
period, which will drive the demand for cellular immunotherapies. However, the high cost of cellular immunotherapy
product manufacturing is expected to restrain the growth. Cellular
immunotherapy involves modified immune cells that make them more sensitive to
differentiate between healthy and cancer tissues. The manufacturing process is
complicated and expensive.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research-based management consulting firm.
“Cellular
Immunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2018-2028 Segmented By Therapy Type (CAR T Cell Therapy, Dendritic
Cell Therapy, NK Cell Therapy, TIL Therapy, Others), By Indication (B-cell
Malignancies, Prostate Cancer, Liver Cancer, Renal Cell Carcinoma, Others), By
End-Use (Hospitals, Cancer Institutes, Others), By Region, By Competition”,
has evaluated the future growth potential of Global Cellular Immunotherapy Market and provides statistics &
information on market size, structure and future market growth. The report
intends to provide cutting-edge market intelligence and help decision makers
take sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in Global Cellular Immunotherapy Market.
Contact
TechSci Research
LLC
420 Lexington
Avenue, Suite 300,
New York, United
States- 10170
Tel:
+1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com